TG Therapeutics (TGTX) Competitors $41.33 +1.03 (+2.56%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$41.42 +0.09 (+0.23%) As of 04/25/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TGTX vs. ONC, SMMT, TEVA, ITCI, GMAB, RDY, ASND, MRNA, VTRS, and QGENShould you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include Beigene (ONC), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. TG Therapeutics vs. Beigene Summit Therapeutics Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Beigene (NASDAQ:ONC) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk. Which has more volatility & risk, ONC or TGTX? Beigene has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Does the media prefer ONC or TGTX? In the previous week, TG Therapeutics had 3 more articles in the media than Beigene. MarketBeat recorded 13 mentions for TG Therapeutics and 10 mentions for Beigene. TG Therapeutics' average media sentiment score of 1.55 beat Beigene's score of 0.43 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beigene 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TG Therapeutics 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is ONC or TGTX more profitable? TG Therapeutics has a net margin of -5.42% compared to Beigene's net margin of -25.94%. TG Therapeutics' return on equity of -8.32% beat Beigene's return on equity.Company Net Margins Return on Equity Return on Assets Beigene-25.94% -25.12% -14.95% TG Therapeutics -5.42%-8.32%-3.40% Which has preferable valuation and earnings, ONC or TGTX? TG Therapeutics has lower revenue, but higher earnings than Beigene. Beigene is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeigene$3.81B6.35-$881.71M-$6.14-39.89TG Therapeutics$329.00M19.95$12.67M$0.14295.21 Do analysts rate ONC or TGTX? Beigene currently has a consensus price target of $318.88, suggesting a potential upside of 30.21%. TG Therapeutics has a consensus price target of $40.67, suggesting a potential downside of 1.60%. Given Beigene's stronger consensus rating and higher possible upside, equities research analysts clearly believe Beigene is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beigene 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Does the MarketBeat Community prefer ONC or TGTX? TG Therapeutics received 651 more outperform votes than Beigene when rated by MarketBeat users. Likewise, 76.27% of users gave TG Therapeutics an outperform vote while only 72.73% of users gave Beigene an outperform vote. CompanyUnderperformOutperformBeigeneOutperform Votes872.73% Underperform Votes327.27% TG TherapeuticsOutperform Votes65976.27% Underperform Votes20523.73% Do institutionals and insiders hold more shares of ONC or TGTX? 48.5% of Beigene shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 6.6% of Beigene shares are held by company insiders. Comparatively, 10.5% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryTG Therapeutics beats Beigene on 13 of the 17 factors compared between the two stocks. Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TGTX vs. The Competition Export to ExcelMetricTG TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.56B$6.71B$5.45B$7.81BDividend YieldN/A3.16%5.43%4.26%P/E Ratio-413.267.2322.3918.44Price / Sales19.95239.71391.43101.46Price / Cash353.9065.8538.1834.62Price / Book38.996.306.684.19Net Income$12.67M$143.17M$3.22B$248.05M7 Day Performance7.85%8.00%6.25%6.54%1 Month Performance2.81%-4.01%-2.70%-1.97%1 Year Performance206.83%-2.24%16.86%4.72% TG Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TGTXTG Therapeutics3.3284 of 5 stars$41.33+2.6%$40.67-1.6%+206.8%$6.56B$329.00M-413.26290Upcoming EarningsNews CoveragePositive NewsONCBeigene3.2272 of 5 stars$229.22-0.8%$316.71+38.2%N/A$22.66B$3.81B-27.829,000Analyst ForecastNews CoverageSMMTSummit Therapeutics2.6584 of 5 stars$25.22+2.5%$35.40+40.4%+508.0%$18.60B$700,000.00-90.07110Upcoming EarningsAnalyst ForecastNews CoverageGap DownTEVATeva Pharmaceutical Industries3.1149 of 5 stars$13.30-2.6%$23.43+76.2%+7.8%$15.08B$16.54B-9.1736,800Analyst UpgradeNews CoveragePositive NewsITCIIntra-Cellular Therapies2.2634 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S4.4477 of 5 stars$20.07+0.1%$39.17+95.2%-26.9%$13.28B$21.53B11.531,660Analyst RevisionRDYDr. Reddy's Laboratories2.0098 of 5 stars$13.68+0.1%$17.00+24.3%-7.4%$11.42B$311.31B21.7824,800Positive NewsASNDAscendis Pharma A/S2.3497 of 5 stars$161.15-2.4%$204.67+27.0%+20.8%$9.83B$363.64M-22.70640Upcoming EarningsNews CoveragePositive NewsMRNAModerna4.3375 of 5 stars$25.13+1.7%$58.70+133.6%-74.8%$9.72B$3.20B-2.713,900Upcoming EarningsNews CoverageGap DownVTRSViatris2.4876 of 5 stars$7.57+0.1%$10.50+38.7%-29.7%$9.04B$14.74B-10.2337,000QGENQiagen3.6509 of 5 stars$40.51-0.5%$47.83+18.1%+4.0%$9.01B$1.98B112.806,030Analyst Revision Related Companies and Tools Related Companies Beigene Alternatives Summit Therapeutics Alternatives Teva Pharmaceutical Industries Alternatives Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Moderna Alternatives Viatris Alternatives Qiagen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TGTX) was last updated on 4/27/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
